XERS - Company ID 0001867096
The table below shows Xeris Biopharma Holdings, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $111.04M | $71.62M | $67.45M | $121.97M | $67.27M |
| Short-term investments | - | $0.00 | $5.00M | $0.00 | $35.16M |
| Receivables | $51.05M | $40.41M | $39.20M | $30.83M | $17.46M |
| Inventory | $68.67M | $48.17M | $38.84M | $24.73M | $18.12M |
| Total current assets | $240.31M | $167.66M | $156.26M | $186.82M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $142.60M |
| Property, plant & equipment | $4.95M | $5.56M | $5.97M | $5.52M | $6.63M |
| Goodwill | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M |
| Total assets | $383.53M | $323.06M | $322.60M | $344.52M | $304.36M |
| Accounts payable | $3.08M | $2.29M | $11.56M | $4.61M | $8.92M |
| Total current liabilities | $109.57M | $100.44M | $95.19M | $73.62M | $79.04M |
| Long-term debt | $220.34M | $217.01M | $190.93M | $187.07M | $88.07M |
| Total liabilities | $369.84M | $352.68M | $329.38M | $299.33M | $209.13M |
| Retained earnings | -$671.31M | -$671.86M | -$617.02M | -$554.77M | -$460.11M |
| Total equity | $13.69M | -$29.61M | -$6.78M | $45.19M | $95.23M |